NCT02604277 Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
| NCT ID | NCT02604277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2016-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 130 participants in total. It began in 2016-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to learn the environmental and psychological factors that impact suicidality in patients diagnosed with Bipolar Disorder. Additionally, the study aims to identify treatments to reduce the suicidal behavior and improve quality of life through a 6-week group-based intervention program.
Eligibility Criteria
Inclusion Criteria: * English speaking * Diagnosis of Bipolar Disorder (BD) * Able to provide written informed consent Exclusion Criteria: * Cognitive impairments * Acutely psychotic * Medically unstable * History of schizophrenia spectrum disorder * History of mood incongruent psychotic symptoms * History of primary substance disorder * History of primary organic disease and/or dementia
Contact & Investigator
Dorian Lamis, PhD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT02604277 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02604277 currently recruiting?
Yes, NCT02604277 is actively recruiting participants. Contact the research team at dorian.lamis@emory.edu for enrollment information.
Where is the NCT02604277 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT02604277 clinical trial?
NCT02604277 is sponsored by Emory University. The principal investigator is Dorian Lamis, PhD at Emory University. The trial plans to enroll 130 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.